Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.51), $0.06 better than the analyst estimate of ($0.57). Revenue for the quarter came in at $4.85 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.